CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02970981
NCT02970981Phase 2Completed
CompareCT.gov

A Pilot Trial of Ipilimumab With Nivolumab for Participants With Resected Stages IIIB/IIIC/ IV Melanoma

NYU Langone Health·interventional·Posted Nov 22, 2016·Updated Apr 30, 2024

In Brief

A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Melanoma. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety and tolerability of treatment with Nivolumab in combination with Ipilimumab in subjects with resected Stages IIIB/IIIC/ IV melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 22, 2016
Enrollment StartNov 29, 2016
Primary CompletionNov 1, 2018
Study CompletionMay 2, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.6 years ago

Interventions

Nivolumabbiological

Ipilimumabbiological